Radar › Companies › Cell Therapy · China
Radar · Cell Therapy in China

Best Cell Therapy Companies in China

The 30 best Cell Therapy companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CARsgen.

30companies tracked
$1.1Bdisclosed funding
0unicorns
20have raised
Sources & further reading
  • ResearchAndMarkets.com

Ranked: Best Cell Therapy companies in China

#CompanyDisclosed fundingLast roundStageFoundedFounderEmployeesPatents & IP focusRecent signals
1CARsgen
Developer of CAR-T cell therapies for the treatment of hematological malignancies and solid tumors
$276M72 mo agoPublic2014Huamao Wang
Co-Founder & COO
525——
2Gracell Bio
Developer of CAR T cell therapies for the treatment of cancer
$195M39 mo agoAcquired2017Wei Cao
Founder & CEO
9——
3OriCell Therapeutics
Developer of immuno-therapeutics for cancer treatment
72Funding top 16%Patents top 27%Moat top 28%Innovation top 34%
All 8 signals ▾
Fundingtop 16%
Patentstop 27%
Moattop 28%
Innovationtop 34%
Newstop 36%
Markettop 37%
Talentbottom 49%
Globalbottom 43%
Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr)
Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21
rank vs industry peers · Fliar Intelligence Index 72/100
$170M7 mo agoSeries D2015He Xiaowen
Co-Founder
15056 patents
Targeted antibody and CAR‑T therapeutics against hematologic/solid tumor antigens
—
4Legend Biotechnology
Developer of cell therapy to treat cancer and infectious diseases
$150M43 mo agoPublic2014Yuan Xu
CEO
1,576——
5Innovative Cellular Therapeutics
Developer of CAR-T cell therapies for blood cancers and solid tumors
$97M62 mo agoSeries C2009Lei Xiao
CEO
1473 patents
Engineered immune cells for enhanced migration, expansion, and checkpoint resistance in cell therapy
—
6Neukio Biotherapeutics
Developer of cell therapies to treat cancer
$50M50 mo agoSeries A2021Liqun Wang
Founder
—9 patents
Therapeutic antibodies and engineered immune cells for cancer immunotherapy
—
7TCRCure Biopharma
Developer of cell therapies to treat cancer
$47M57 mo agoSeries B2016—7051 patents
Engineered immune cell therapies with synthetic cytokine receptors and checkpoint antibodies
—
8Shize Bio
Developer of stem-cell therapies to treat neurodegenerative diseases
42Funding top 33%Growth top 35%Talent top 38%Moat top 48%
All 7 signals ▾
Fundingtop 33%
Growthtop 35%
Talenttop 38%
Moattop 48%
Marketbottom 48%
Globalbottom 29%
Techbottom 16%
Funding: Raised $41.7M across 2 rounds · 2 rounds over 4 yrs (0.5/yr)
Growth: Fresh capital in last 24 mo
rank vs industry peers · Fliar Intelligence Index 42/100
$42M24 mo agoSeries B2021Michael Lee
Founder & CEO
100——
9Huaxia Yingtai Biotechnology
Developer of CAR-T cell therapies for treating cancer
$38M61 mo agoSeries B2018Lin Xin
Founder
———
10Hebei Senlang Biotechnology
Developer of CAR-T cell based immunotherapy for cancer
$30M54 mo agoAcquired2017—16021 patents
Nanobody-based CAR immunotherapies targeting CD7, CLDN18.2, and BCMA for cancer treatment
—
11Starna Therapeutics
Developer of RNA-based drugs for multiple diseases
29Funding top 34%Moat top 38%Talent bottom 49%Market bottom 37%
All 5 signals ▾
Fundingtop 34%
Moattop 38%
Talentbottom 49%
Marketbottom 37%
Globalbottom 36%
Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr)
Moat: Editorial + unicorn rating 4/10 · Soonicorn
rank vs industry peers · Fliar Intelligence Index 29/100
$22M13 mo agoSeries B2021Rongkuan Hu
Founder
———
12Nk-Celltech
Provider of immuno-oncologic drugs for cancer
40Market top 45%Funding top 46%Global bottom 38%
All 3 signals ▾
Markettop 45%
Fundingtop 46%
Globalbottom 38%
Market: 60 employees (top 31% of Life Sciences)
Funding: Raised $14.9M across 2 rounds · 2 rounds over 4 yrs (0.5/yr)
rank vs industry peers · Fliar Intelligence Index 40/100
$15M16 mo agoSeries A2020—60——
13Nanjing CART Medical Technologies
Developer and provider of CAR T cell therapy related technologies and services
$10M57 mo agoSeries A2017Enxiu Wang
Founder
———
14Chengdu Kangjing Biotechnology
Developer of stem cell and immune cell therapy technology
$4M145 mo agoSeed2013—60——

Top 12 Cell Therapy companies in China

#1
Series D · Pudong, Shanghai · founded 2015 · 150 employees
$170Mraised
▾

Developer of immuno-therapeutics for cancer treatment. It offers CAR-T- based therapies and antibodies for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, non-small cell lung cancer, and others.

Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 16%
Patents
top 27%
Moat
top 28%
Innovation
top 34%
News
top 36%
Market
top 37%
Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series D (Apr 2026)
Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: TCE Senior Scientist, Senior Scientist (In vivo CAR-T)
Funding rounds
  • Apr 2026Series D$110M
  • Jan 2026Series C$70M
  • Feb 2023Series B$45M
  • Aug 2022Series B$125M
Founders & team
He XiaowenCo-Founder
Investors
RTW Investments, Qatar Investment Authority, Qiming Venture Partners, C&D, Quan Capital, Sinopharm Capital
#2
Series B · Suzhou, Jiangsu · founded 2021
$22.1Mraised
▾

Developer of RNA-based drugs for multiple diseases. The company focuses on the development of innovative drugs and vaccines with RNA as the core for infectious diseases, tumor immunology, and metabolic diseases.

Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 34%
Moat
top 38%
Talent
bottom 49%
Market
bottom 37%
Global
bottom 36%
Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series B (Oct 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 417 LinkedIn followers
Funding rounds
  • Oct 2025Series B$44M
  • May 2022Series A$22.1M
  • Dec 2021Angel—
Founders & team
Rongkuan HuFounder
Investors
LYFE Capital, Source Code Capital, Hony Capital, Hillhouse, Sherpa Healthcare Partners, Hua Chuang Capital
#3
Series A · Pudong, Shanghai · founded 2020 · 60 employees
$14.9Mraised
▾

Provider of NK cell therapy for treating cancer, cellular drugs to precisely target of tumors and tumor immune microenvironment (TIME)

Fliar Intelligence Index™ 40how this company ranks against its industry peers
Market
top 45%
Funding
top 46%
Global
bottom 38%
Market: 60 employees (top 31% of Life Sciences)
Funding: Raised $14.9M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series A (Jul 2025)
Global: Investors from 3 countries beyond China
Funding rounds
  • Jul 2025Series A$13.9M
  • Jul 2022Series A$14.9M
Investors
Huagai Capital, Sirius Capital, QJ Capital, Unifortune, CASVC
#4
Series B · Minhang, Shanghai · founded 2021 · 100 employees
$41.7Mraised
▾

Developer of stem-cell therapies to treat neurodegenerative diseases. By using gene-editing technology, the company has engineered a pluripotent stem cell platform to develop therapeutics for degenerative diseases such as Parkinson's disease.

Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 33%
Growth
top 35%
Talent
top 38%
Moat
top 48%
Market
bottom 48%
Global
bottom 29%
Funding: Raised $41.7M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Oct 2024)
Growth: Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding rounds
  • Oct 2024Series B$14M
  • Apr 2023Series A—
  • Nov 2022Series A$27.7M
  • Jan 2022Seed—
Founders & team
Michael LeeFounder & CEOLi XiangCEO
Investors
Qiming Venture Partners, zxrc, Yuanhe Holdings, Yuanheholdings, LAV Asset Management, HSG
Tech stack
Animate.CssGsapJqueryLayuiLottiefilesPhp
#5
Acquired · Shanghai, Shanghai · founded 2017 · 9 employees
$195.2Mraised
▾

Developer of CAR T cell therapies for the treatment of cancer. The company has developed a gene-editing platform to produce multiplex CAR T cell therapies such as FasTCAR, TruUCAR, and Donor-derived CAR for multiple myeloma, lymphoma, and leukemia. The company is also working on a combination of CAR-T with co-stimulatory factors.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers — 2.9% of this cohort's audience
Funding rounds
  • Aug 2023Post IPO—
  • Oct 2020Series C$100M
  • Feb 2019Series B$85M
  • Sep 2018Series A$10.2M
Founders & team
Wei CaoFounder & CEO
Investors
Lilly Asia Ventures, 6 Dimensions Capital, Temasek, Kingdon Capital Management, Vivo Capital, Adage Capital Management
Tech stack
Baidu Analytics (百度统计)BootstrapFlickityHammer.JsHugoJquery
#6
Public · Nanjing, Jiangsu · founded 2014 · 1576 employees
$150.4Mraised
▾

Developer of cell therapy to treat cancer and infectious diseases. The company focused on developing CAR-T cell therapies for hematologic malignancies, solid tumors, and infectious diseases.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 164k LinkedIn followers — 87.6% of this cohort's audience
Funding rounds
  • Apr 2023Post IPO$200M
  • Mar 2020Series D$150.4M
Founders & team
Yuan XuCEO
Investors
Hudson Bay Capital, RA Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, HTIF, Vivo Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAkamaiAmazon Web ServicesApache Http ServerApple Icloud Mail
#7
Public · Shanghai, Shanghai · founded 2014 · 525 employees
$276Mraised
▾

Developer of CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. The company's lead product is KJgpc3-001, a glypican-3 (GPC3)-directed CAR-T cell therapy for liver cancer, and is also advancing CAR-T therapies for lung and brain cancers in parallel.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 13k LinkedIn followers — 7.2% of this cohort's audience
Activity: 1 product launches · 1 partnerships (incl. Dispatch Bio) announced in 12 mo
Funding rounds
  • Nov 2020Series C$186M
  • Mar 2018Series B$60M
  • Jan 2016Series B$30M
  • Nov 2014Series A—
Founders & team
Huamao WangCo-Founder & COO
Investors
DAOL Investment, Photon Fund, BioVeda China Fund, Shiyu, Lilly Asia Ventures, Loayal Valley Capital
#8
Series C · Shanghai, Shanghai · founded 2009 · 14 employees
$97.1Mraised
▾

Developer of CAR-T cell therapies for blood cancers and solid tumors. The company has a CoupledCAR technology platform to develop a pipeline of drugs for colorectal, thyroid, pancreatic, and lung cancer.

Funding rounds
  • Sep 2021Series C$40M
  • Dec 2019Series B$28.6M
  • Apr 2018Series B$28.5M
Founders & team
Lei XiaoCEO
Investors
Volcanics Venture, SBCVC, ShenZhen GTJA Investment Group, Witruth Capital, LH Ventures, CDH
Tech stack
WordpressMysqlPhpApache Http Server
#9
Series A · Shanghai, Shanghai · founded 2021
$50Mraised
▾

Developer of cell therapies to treat cancer. The company leverages gene-editing technologies and focuses on the development of iPSC-CAR-NK immune cell therapies to treat cancer patients.

Funding rounds
  • Sep 2022Series A$50M
Founders & team
Liqun WangFounder
Investors
CD Capital Asset Management, Alwin Capital, Surplus Capital Agency, Lilly Asia Ventures, IDG Capital, Sherpa Healthcare Partners
#10
Series B · Beijing, Beijing · founded 2016 · 70 employees
$47.3Mraised
▾

Developer of cell therapies to treat cancer. The company has developed a T cell engineering platform that enables antigen-specific TCR cloning, T cell genetic engineering, and TCR repertoire analysis. They are planning to initiate clinical trials for the treatment of HPV-related cervical and head/neck cancers.

Funding rounds
  • Feb 2022Series B$47.3M
  • Apr 2019Series A—
  • Dec 2018Series A—
  • 2017Series A—
Investors
Emerging Technology Partners, Jiangxi Kangdao Biological, CCB Financial Assets Investment, Share Capital, Detong Capital, Yueyin Medical Fund
#11
Acquired · Shijiazhuang, Hebei · founded 2017 · 160 employees
$29.6Mraised
▾

Hebei Senlang Biotechnology is developing immunotherapy-based technology to treat cancer. They have developed an immunotherapy platform based on CAR-T/TCR-T, universal CAR-GDT, and CAR-HSPC-NK technology. Their lead candidate CD19 CAR-T, has completed preclinical phase which is being investigated for hematological tumor.

Funding rounds
  • May 2022Series C$29.6M
  • 2018Series B—
Investors
Qianhai Ark Asset Management, CEC Capital
#12
Series B · Haidian, Beijing · founded 2018
$37.5Mraised
▾

Developer of CAR-T cell therapies for treating cancer. The company has T cell transformation technology platforms, STAR-T and TCR-T, and has built a mature industrialization platform for process development and quality control. It is developing pipeline of products for treatment of hematological tumors and other indfectious diseases.

Funding rounds
  • Oct 2021Series B$31M
  • Jan 2020Series A$6.5M
Founders & team
Lin XinFounder
Investors
CCB Capital Management, Guanghua Venture Capital, Huacheng Holdings Group, Vertex Ventures, Tao Capital, Sangel Capital

Funding & investor landscape

$1.1Btotal disclosed funding
14companies funded
28disclosed rounds
0rounds last 90 days
Most active investors
Lilly Asia Ventures5 rounds
Vivo Capital3 rounds
HTIF2 rounds
Hua Chuang Capital2 rounds
Huagai Capital2 rounds
Qiming Venture Partners2 rounds
Quan Capital2 rounds
RA Capital Management2 rounds
Sequoia Capital China2 rounds
Sherpa Healthcare Partners2 rounds

Notable founders

He Xiaowen
Co-Founder · OriCell Therapeutics
Rongkuan Hu
Founder · Starna Therapeutics
Michael Lee
Founder & CEO · Shize Bio
Li Xiang
CEO · Shize Bio
Wei Cao
Founder & CEO · Gracell Bio
Yuan Xu
CEO · Legend Biotechnology
Huamao Wang
Co-Founder & COO · CARsgen
Lei Xiao
CEO · Innovative Cellular Therapeutics
Liqun Wang
Founder · Neukio Biotherapeutics
Lin Xin
Founder · Huaxia Yingtai Biotechnology
Enxiu Wang
Founder · Nanjing CART Medical Technologies
Junying Yu
Founder · Nuwacell
Prism market signals · China · country-scoped Prism corpus, 90,390 docs

Market landscape — 10 sub-themes by coverage

Share of Cell Therapy coverage by sub-theme.

Regulatory-risk over time rising

Funding & growth over time

funding rising · growth rising

Common questions

How many Cell Therapy companies are there in China?
Radar tracks 30 indexable Cell Therapy companies headquartered in China that meet our profile-completeness bar.
What is the total funding raised by Cell Therapy companies in China?
The Cell Therapy companies in China on this list have raised a combined $1.1B in disclosed equity funding across 14 funded companies.
Which is the highest-funded Cell Therapy company in China?
CARsgen is the highest-funded Cell Therapy company in China, with $276M in disclosed equity funding.
How many Cell Therapy companies in China are funded?
14 of the 30 Cell Therapy companies in China on this list have disclosed at least one equity funding round.
How many Cell Therapy unicorns are there in China?
None of the Cell Therapy companies in China on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in China Cell Therapy companies?
The most active investors in China Cell Therapy companies on this list include Lilly Asia Ventures, Vivo Capital, HTIF, Hua Chuang Capital, Huagai Capital.
Rohit KhannaTrends & Stories

Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.

Coming soon